Daily non-political popular news in brief.

Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half

Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.

Read more »

Keywords: data, show, treatment, remicade, reduced, hospitalizations, ulcerative, colitis, patients, half, hospitalization, coliti, patient

« Previous | Next »

Similar news on "Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half":

1. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
   10-15-2007 · EurekAlert!
   REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis. According to a primary analysis of long-term extension data from the Active Ulcerative Colitis 1 and 2 trials, there is a 41 percent reduction in the incidence of colectomy, the surgical removal of the colon, in patients receiving REMICADE through 54 weeks, compared to those receiving placebo.
   Similar news · Read more »
   
2. Survey indicates people with chronic moderate to severe plaque psoriasis may be undertreated
   02-02-2007 · EurekAlert!
   The National Psoriasis Foundation and Amgen today released data, which show that nearly 40 percent of patients with chronic moderate to severe psoriasis are not currently receiving any treatment. Further, more than half of moderate to severe patients on treatment are not being treated in accordance with AAD guidelines, which state that patients diagnosed with chronic moderate to severe plaque psoriasis are candidates for phototherapy or systemic therapy, including biologic agents.
   Similar news · Read more »
   
3. Asacol treats UC symptoms of isolated proctitis
   12-05-2007 · EurekAlert!
   Data from two Phase III clinical trials support that Asacol, an oral, nonsteroidal medication that belongs to the class of agents known as 5-aminosalicylic acids, is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis, including isolated proctitis.
   Similar news · Read more »
   
4. New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
   02-02-2007 · EurekAlert!
   Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving Remicade (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75).
   Similar news · Read more »
   
5. HORIZONS AMI trial data will help set guidelines
   10-24-2007 · EurekAlert!
   Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation, show that the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduces net adverse clinical events by 24 percent compared to the standard treatment, and significantly reduces major bleeding that occurs after angioplasty by 40 percent.
   Similar news · Read more »
   
6. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
   10-15-2007 · EurekAlert!
   Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at the American College of Gastroenterology meeting in Philadelphia.
   Similar news · Read more »
   
7. New study shows Actonel almost halves the risk of hip fractures compared to alendronate
   11-17-2006 · EurekAlert!
   Data published today from a retrospective study of over 33,000 postmenopausal women showed that among patients newly prescribed one of the two most popular osteoporosis treatments, patients taking Actonel® (risedronate sodium) were approximately half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment. These results were published today in the peer-reviewed journal Osteoporosis International.1
   Similar news · Read more »
   
8. Rapid-acting insulin analogues in diabetes mellitus type 1 -- Superiority not proven
   07-17-2007 · EurekAlert!
   There is currently no evidence available of a superiority of rapid-acting insulin analogues over human insulin in the treatment of adult patients with diabetes mellitus type 1. The evidential value and design of studies available so far are inadequate and do not allow conclusions regarding most patient-relevant therapy goals, such as the reduction in long-term complications or overall mortality. Due to the lack of data, the benefit of rapid-acting insulin analogues in children and adolescents is unclear.
   Similar news · Read more »
   
9. New findings show Enbrel significantly reduced levels of C-reactive protein
   02-01-2008 · EurekAlert!
   Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein, a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group. These results will be presented today at the American Academy of Dermatology Scientific Meeting in San Antonio, Texas.
   Similar news · Read more »
   
10. Fosrenol data show evidence of trends towards improved bone formation in CKD stage 5 patients
    11-17-2006 · EurekAlert!
    Treatment with the phosphate binder Fosrenol, lanthanum carbonate, was associated with slight improvements in bone formation in chronic kidney disease stage 5 patients with high phosphorus levels in the blood, according to long-term data presented at the American Society of Nephrology meeting. Additional studies presented at ASN document the efficacy and safety of the reformulated and higher-dose FOSRENOL tablets. Of the approximately 20 million Americans who have some form of kidney disease, more than 530,000 have developed CKD Stage 5.
    Similar news · Read more »